Company Imm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic

– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 –

United statesIdexork xorkBlaine davisSelecta biosciencesCarsten brunnEuropean congressExchange commissionDevelopment expensesCompany immEuropean alliance of associations rheumatologyCompany proprietary tregCompany board of directorsChronic refractory gout in partnershipStrategic initiative overviewSelecta biosciences incBiologics license application

Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics

Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesBlaine davisIdexork xorkSelecta biosciencesCarsten brunnDevelopment expensesChronic refractory gout in partnershipEuropean congressExchange commissionEuropean alliance of associations rheumatologyCompany immCompany board of directorsCompany proprietary tregStrategic initiative overviewSelecta biosciences incBiologics license application

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB (2)

75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of.

United statesCarsten brunnAnders ullmanThomas kudsk larsenheadSelecta biosciencesGuido oelkersPeter traberPrnewswire selecta biosciences incSobi investor relations teamExchange commissionCompany immSelecta biosciences incHead of research developmentChief medical officerChief executive officerMedical affairs

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB (3)

75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of.

United statesCarsten brunnAnders ullmanThomas kudsk larsenheadSelecta biosciencesGuido oelkersPeter traberPrnewswire selecta biosciences incSobi investor relations teamExchange commissionCompany immSelecta biosciences incHead of research developmentChief medical officerChief executive officerMedical affairs

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB

/PRNewswire/ Selecta Biosciences, Inc. (NASDAQ: SELB) and Sobi®, today announced positive topline results from the Phase 3 DISSOLVE I & II placebo.

United statesCarsten brunnAnders ullmanBlaine davisSelecta biosciencesThomas kudsk larsenGuido oelkersPeter traberSobi investor relations teamExchange commissionCompany immSelecta biosciences incHead of research developmentChief medical officerChief executive officerMedical affairs